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Abstract
In Portugal, tetrahydrobiopterin (BH4)-responsive patients with phenylketonuria (PKU) are identified using a loading test (LT).
Phenylalanine/natural protein (Phe/NP) intake is increased to elevate blood Phe prior to the LT. In a longitudinal retrospective
study, the impact of Phe/NP titration post-LT in 58 patients (19.6 + 8.2 years) with PKU during 4 study periods (SPs) was
examined. In SP1 (2010-2013), patients were diet treated only; in SP2 (2014), the Phe/NP titration was followed by the LT in SP3
(2015). In SP4 (2016), patients received diet treatment only (n ¼ 49) or BH4 þ diet (n ¼ 9). The median percentage blood Phe
within the target range was higher in SP1 versus SP4 (64 [28-85] vs 45 [0-66]; P < .001). Our results suggest that transient Phe/NP
titration, associated with a deliberate increase in NP, may adversely affect metabolic control. Controlled studies are necessary to
examine the longer term impact of temporary increased NP with BH4 LT in non-BH4-responsive patients.
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Introduction
Phenylketonuria (PKU) is an autosomal recessive inborn error
of phenylalanine (Phe) metabolism, affecting 1:10 000 people
in Europe, caused by deficiency of phenylalanine hydroxylase
(PAH) enzyme.1,2 The conversion of Phe (either from diet or
endogenous catabolism) into tyrosine is compromised, result-
ing in increased blood Phe. In PKU, diet is the primary treat-
ment, involving a severe restriction of Phe and natural protein
(NP) and replacement of non-Phe protein with a protein sub-
stitute (PS) and low-protein foods (including special low-
protein foods) to satisfy energy needs.3,4 In Portugal, PS are
available as Phe-free amino acid supplements, low Phe
glycomacropeptide-based PS, or large neutral amino acids.5
Maintaining life-long adherence to this restricted diet is
challenging, especially in older children.6 It is well established
that there is deterioration in metabolic control over time, par-
ticularly in late adolescence and adulthood.6–9
More recently, it has been established that the administration
of pharmacological doses of tetrahydrobiopterin (BH4), the PAH
cofactor, available as a commercial formula of sapropterin dihy-
drochloride (Kuvan), may help improve metabolic control,
improving dietary Phe tolerance in a subset of patients with mild
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or moderate PKU.10–12 Tetrahydrobiopterin responsiveness is
established either by genotype or with a loading test (LT).1
Although different methodologies are used to evaluate BH4
responsiveness, a 48-hour BH4 LT protocol is commonly advo-
cated in Europe, analyzing blood Phe before and after a single
daily dose of sapropterin (20 mg/kg/d) on 2 consecutive days.13,14
In Portugal, the Portuguese Society for Metabolic Disorders
(SPDM) specifies that all potential BH4 responders should be
identified using a LT. Prior to the LT, Phe/NP intakes are
increased to elevate blood Phe to >480 μmol/L. Sometimes
this procedure is challenging both for patients and profession-
als15 associated with undefined individual Phe tolerance prior
to LT and patient ability to eat the amount of higher protein
foods that may be necessary to increase blood Phe. The length
of time that it takes to increase Phe levels varies between
individual patients. Opinion varies on the source of NP that
should be given. No published studies have conducted con-
trolled trials to investigate the effect of short-term increase in
dietary Phe/NP intake on long-term blood Phe, particularly in
non-BH4 responders. In a longitudinal, retrospective study
over 6 years, we aimed to examine the impact of Phe/NP titra-
tion on metabolic control post-LT in patients with PKU.
Methods
Participants
In 2015, 66 patients with PKU completed a LT from the Refer-
ence Center of Inherited Metabolic Diseases of Centro Hospita-
lar do Porto. Eight patients were excluded from the study: 5 were
late diagnosed (late treated patients with inconsistent dietary
adherence), 2 had insufficient clinical data and dietary records,
and 1 had Down syndrome with severe neurological impairment
affecting dietary management.16 The final sample included 58 (n
¼ 58) early treated patients (4-34 years; 19.6+ 8.2 years; 50%
females). Disease severity was classified according to the neo-
natal blood Phe, at newborn screening, as stated in the Portu-
guese Consensus17: hyperphenylalaninemia (blood Phe <6 mg/
dL), mild PKU (blood Phe 6 mg/dL and 20 mg/dL), and
classical PKU (blood Phe >20 mg/dL). There were 30 (51.7%)
patients with mild PKU and 28 (48.3%) patients with classical
PKU. The blood Phe target range was 6 or 8 mg/dL with
patients aged <12 or 12 years, respectively.17
The final sample of patients was studied in 4 different study
periods (SPs). During SP1 (2010-2013), all patients were on a
low Phe diet. In SP2 (2014), the NP prescription was increased
to define maximum Phe tolerance to establish a blood Phe >480
μmol/L, according to SPDM protocol. During this period, in
patients whose blood Phe was <480 μmol/L, NP intake was
increased initially by adding regular cow milk to the PS. This
was then followed by adding controlled amounts of regular
foods, such as bread, pasta, or other dairy products. The PS
was maintained and the intake of special low-protein foods was
decreased as equivalent regular foods were introduced. A time
period of 8 weeks was allocated to stabilize blood Phe >480
μmol/L in order to initiate the test.
In the SP3 (2015), the preparation for LT was continued and
patients were gradually enrolled, so all of them completed the
test during the year 2015. Additionally, some responders
started BH4 treatment immediately after the LT. In the SP4
(2016), patients were either exclusively diet treated (n¼ 49) or
on BH4 treatment in combination with diet (n ¼ 9).
Study Design
This is a longitudinal retrospective study, with data collected
from 2010 to 2016. Gender, birthdate, newborn screening
blood Phe, disease severity, genotype, date of LT, and BH4
responsiveness were collected from electronic patient clinical
records. Participants were identified by a code, preventing
patient identification. There was no control group as all patients
with PKU had a LT.
Data Collection
Anthropometry. Data on anthropometry were collected from
clinical records from the final nutritional appointment of each
SP. Weight and heights were measured when patients were in
light clothing only, without shoes and accessories. Seca mea-
suring scales (accuracy¼ 0.5 kg) and a stadiometer (measuring
scale ¼ 1 mm) were used. Body mass index (BMI) was calcu-
lated as weight (kg)/height2 (m) and classified by World Health
Organization criteria.18 Anthro (Version 3.2.2) and Anthro Plus
(Version 1.0.4) software were used to calculate BMI z scores
for patients aged between 0 to 5 and 5 to 19 years, respectively.
For patients aged 0 to 5 years, overweight was defined when
BMI z score was >2 standard deviations (SDs).19,20 In patients
aged between 5 and 19 years, overweight was characterized
when BMI z score was >1 SD.20,21
Nutritional intake. Data on dietary intake were collected from the
final nutritional appointment of each SP. Natural protein (g/kg/
d), protein equivalent (PE) from PS (g/kg/d), and total protein
(TP; g/kg/d) intakes were calculated. Additionally, data on
quantitative NP intake (g/kg/d) were collected from the last
register before the LT.
Metabolic control. All patient blood Phe measurements con-
ducted in SP1, SP2, SP3, and SP4 were collected from the
patient database. Blood Phe was measured from blood spots
by tandem mass spectrometry. The samples were collected by
patients in the morning when fasted. Patients were advised to
take weekly blood spots. Blood Phe measurements in each of
the 4 SP were calculated for median, mean, and SD of blood
Phe. Furthermore, for each period and each patient, the per-
centage of blood Phe measurements within target range was
calculated. Whenever patients reached 12 years (n ¼ 14), the
upper target range was adjusted, so results were correctly inter-
preted for age.17 Additionally, for patients who were not BH4
responsive and so not taking BH4 treatment in 2016, the per-
centage of blood Phe measurements within target range before
and after the LT was compared. In contrast, for patients who
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were BH4 responsive and on BH4 treatment in 2016, the per-
centage of blood Phe measurements within target range before
the LT and after the BH4 introduction was compared.
Ethical Statement
This study and its data collection were approved by the ethics
committee of Centro Hospitalar do Porto, on May 18, 2015, to
the investigation project “Trends in Nutritional Status of
patients with phenylketonuria”, with the reference 2015.101
(092-DEFI/087-CES). Written informed consent was obtained
from each patient or caregiver.
Statistical Analysis
IBM SPSS Statistics 24 for Windows was used for statistical
analyses. Kolmogorov-Smirnov test was done to evaluate normal
distribution of variables. Categorical variables were presented as
absolute values or percentage, and continuous variables were
presented as mean+ SDs or as medians [P25-P75], according to
its distribution. Wilcoxon test and Mann-Whitney test were used
to identify differences when non-normal distribution was found.
The level of significance considered was P < .05.
Results
The patient’s characteristics are described in Table 1.
Change in NP Intake
The NP intake (g/kg/d) remained similar between the 4 SPs
(0.58+ 0.3 vs 0.53+ 0.3 vs 0.50+ 0.3 vs 0.55+ 0.3), with a
trend to a lower PE intake (g/kg/d; 1.12+ 0.4 vs 0.95+ 0.3 vs
0.92 + 0.3 vs 0.84 + 0.3), which is reflected in a lower TP
intake (g/kg/d) in SP4 (1.72+ 0.4 vs 1.49+ 0.3 vs 1.46+ 0.4
vs 1.41+ 0.3). However, from SP1 to LT, NP (g/kg/d) intake
was increased by 0.14+ 0.5 (Table 2).
Change in Blood Phe
Median blood Phe was lower in SP1 than in SP4 (6.80 [4.70-
10.30] vs 7.91 [6.53-11.11]; P < .001; Table 3). The percentage
of blood Phe measurements within target range was higher in
SP1 compared with SP4 (64% [28-85] vs 45% [0-66]; P < .001;
Table 3). In SP4, 16 (27.6%) patients did not have any blood
Phe measurement within the target range compared with 6
(10.3%) patients in SP1. Changes in blood Phe control through-
out the study are illustrated in Figure 1.
In SP1, there were almost twice as many patients in good
metabolic control (39.7%) compared to SP4 (22.4%; Table 4).
Table 5 presents data on percentages of blood Phe measure-
ments within target range at SP1 and SP4, for patients on BH4
treatment þ diet and diet treatment only. In these subgroups,
the median differences between SP1 and SP4 were 1 [46 to
22] and 17 [33 to 0], not reaching statistical significance
(P ¼ .408). The percentage of blood Phe measurements within
target range in the BH4 treated þ diet group in 2016, after
starting BH4 (responders, n ¼ 9), remained stable when com-
pared to the SP1 pre-LT phase (85 [51-95] vs 81 [58-88];
P ¼ .953). In the non-BH4 responder group (n ¼ 49) who were
prescribed a low Phe diet, there was a post-LT deterioration of
metabolic control compared with the pre-LT phase (44 [5-63]
vs 51 [22-71]; P ¼ .001).
Thirty-one (53.4%) of the 58 patients were already adults
(aged 18 years) at SP1. Their metabolic control deteriorated
from SP1 to SP4, median blood Phe increased (9.80 [6.90-
12.50] vs 10.35 [7.10-14.30]; P ¼ .037), and the percentage
of blood Phe measurements within target range was reduced
(32% [3-77] vs 3% [0-60]; P ¼ .026).
Overweight and Obesity
There was no change in the prevalence of overweight or obesity
in patients <5 years, whereas it increased in adults (Table 6).
None of the patients who were overweight or obese in 2013
became normal weight in 2016 (data not shown). This was
irrespective of treatment.
Table 1. Gender, Age, and Disease Severity of Patients Studied.
Sample size N ¼ 58
Gender Female: n ¼ 29 (50%)
Male: n ¼ 29 (50%)
Age (at LTa—2015) 19.6+ 8.2 years (minimum ¼ 4 years;
maximum ¼ 34 years)
<19 years: n ¼ 24 (41.4%)
≥ 19 years: n ¼ 34 (58.6%)
Disease severity Mild PKU: n ¼ 30 (51.7%)
Classical PKU: n ¼ 28 (48.3%)
Abbreviations: LT, loading test; PKU, phenylketonuria.
aLT—tetrahydrobiopterin (BH4) loading test.
Table 2. Natural Protein Intake Differences Between LT and SP1.
Protein intake SP1 LT
Natural protein intake, g/kg/d 0.58+ 0.3 0.72 + 0.4
Difference NPLT  NP2013 ¼ 0.14+ 0.5
Abbreviations: LT, loading test; NP, natural protein; SP1, study period 1.
Table 3. Metabolic Control of Patients During the 4 Periods of the
Study.
Metabolic Control SP1 SP2 SP3 SP4
Median [Phe],
mg/dL
6.80 7.98 8.20 7.91
P25 ¼ 4.70 P25 ¼ 5.85 P25 ¼ 6.80 P25 ¼ 6.53
P75 ¼ 10.30 P75 ¼ 10.58 P75 ¼ 10.25 P75¼ 11.11
Phe measurements
within target
range, %
64 47 38 45
P25 ¼ 28 P25 ¼ 7 P25 ¼ 18 P25 ¼ 0
P75 ¼ 85 P75 ¼ 76 P75 ¼ 62 P75 ¼ 66
Abbreviations: P25, 25th percentile; P75, 75th percentile; Phe, phenylalanine; SP,
study period.
Sousa Barbosa et al 3
Discussion
This was a longitudinal retrospective study that suggested that
patients receiving a BH4 LT, with a temporary increase in NP
pretest, had worse Phe control 1 year posttest, although there
was a trend toward a slight improvement with time. Both the
percentage of blood Phe measurements within target range at
SP1 compared with SP4 and the contrast between percentage of
patients under good metabolic control in SP1 and SP4 support
our conclusions.
We recognize that many factors may have led to deteriora-
tion in blood Phe control in addition to BH4 LT. Diet treatment
for patients with PKU is very restrictive and PS’s have a strong
taste and odor, so adherence is challenging.7,8 After the age of
10 years, dietary adherence is particularly difficult, associated
with transition to self-care, rebellion, and hunger.6,7 Accord-
ingly, a progressive deterioration in metabolic control with age,
particularly in adolescents, is seen in most patients.1,6,8 During
adolescence, there is usually some diet relaxation and food
pleasure and socialization becomes more important, and in
adulthood, the time constraints and stress associated with food
preparation balanced with work, study, or parenthood are dif-
ficult to align.9 Considering that during the 4 SPs our cohort of
patients increased in age, it seemed more appropriate to ana-
lyze the percentage of blood Phe measurements within target
range rather than median blood levels, as target ranges are
already age adjusted.17
We expected that metabolic control of non-BH4 responders
could be maintained post-LT, once the usual low Phe diet was
introduced, but most of the nonresponders had deterioration
in their metabolic control. Generally, adults with PKU who
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Figure 1. Change in blood Phe. Phe denotes phenylalanine.
Table 4. Metabolic Control Quality.a,b
Metabolic Control
(% of Patients
per Class)
SP1 SP4
<75%
“Bad
Control”
≥ 75%
“Good
Control”
<75%
“Bad
Control”
≥ 75%
“Good
Control”
60.3 39.7 77.6 22.4
Abbreviations: Phe, phenylalanine; SP, study period.
aPhe measurements within target range ≥ 75%—“good control.”
bPhe measurements within target range <75%—“bad control.”
Table 5. Metabolic Control of Patients on and Without BH4 Treat-
ment in 2016.a
Metabolic Control (% of Phe Measurements Within Target Range)
On BH4 Treatment
in 2016 (n ¼ 9)b
Without BH4 Treatment
in 2016 (n ¼ 49)
SP1 SP4 SP1 SP4
90 83 58 41
P25 ¼ 65 P25 ¼ 48 P25 ¼ 21 P25 ¼ 0
P75 ¼ 97 P75 ¼ 91 P75 ¼ 80 P75 ¼ 57
Median differences ¼
1 [46 to 22]
Median differences ¼
17 [33 to 0]
Abbreviations: BH4, tetrahydrobiopterin; P25, 25th percentile; P75, 75th per-
centile; Phe, phenylalanine; SP, study period.
aThis table only represents patients on medication in 2016.
bSome patients have responded to loading test but only initiated medication
during/after 2016 or stopped medication (n ¼ 6).
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usually follow the same restrictive dietary patterns from day-
to-day are anticipated to maintain long-term consistent blood
Phe concentrations so the increase in their blood Phe following
an unsuccessful BH4 LT was unexpected.
The choice of foods for increasing NP intake for the Phe
titration may have influenced the results. Increasing Phe intake
using milk sources (as previously recommended) together with
PS was not practical in older patients.15 In many adult patients
with PKU, a liquid PS was prescribed but it was not feasible to
mix this with other NP sources. In milder patients with PKU,
higher pre-LT Phe tolerance was observed, so foods with a high
protein content was given to temporarily increase Phe/NP
intake, for example, regular bread and pasta, milk, cheese, and
yogurt. Although some patients were afraid to introduce high-
protein foods into their daily routine, others enjoyed their
taste.22 We cannot rule out the negative psychological conse-
quences on feeding behavior of giving additional NP and then
withdrawing it again from nonresponders. The difficulty and
disappointment in returning to their previous dietary restric-
tions should not be underestimated in nonresponders.15
Although this aspect requires further study, it is naive to con-
sider that it would have no impact. We also observed that
some adult patients also decreased the frequency of blood spot
monitoring (data not shown), which may be associated with
lower motivation because of not responding to BH4 medica-
tion. The PKU European guidelines suggest that a LT should
not be performed in patients with 2 known disease null muta-
tions or 2 known BH4 responsive mutations.1 Our results
demonstrate that by enrolling every patient with PKU to a
LT, independent of the genotype, as suggested by the SPDM,
this may have potential adverse consequences on longer term
metabolic control.
In the process of Phe titration, PS prescription was main-
tained during preparation for LT. However, considering the
weight variations throughout the study (Table 6), stabilizing
PS prescription resulted in a lower TP (g/kg) intake. Also, the
observed weight changes may have justified an increase in PE
prescription, to theoretically prevent any negative effect on
metabolic control.
Our study has several limitations. First, there was no oppor-
tunity to identify the exact starting date of the LT preparation
phase, because some patients already had a higher blood Phe
prior to the LT. Also this was a retrospective study without a
control group, so we were unable to compare the results with a
group of patients not undertaking a LT. Although we have used
the percentage of blood Phe measurements within target range,
which is already age adjusted, our group had a wide age range
which may have influenced adherence and metabolic control.
Finally, in SP4, the comparison between BH4 treated þ diet
and exclusively diet-treated patients should be interpreted care-
fully due to the small group of patients on drug treatment.
However, this is the first study evaluating the effect of the
LT procedures on metabolic control, involving patients from
one reference treatment center and collecting data from the
year following the LT, suggesting that prospective, controlled,
and multicentric studies are needed to study this aspect further.
It is also important to address the psychological impact of the
LT. It is well established that in older patients with PKU fol-
lowing relaxed diets, they have difficulty recommencing strict
dietary treatment, thereby this knowledge should be considered
when conducting BH4 LT in PKU.
Conclusion
In conclusion, our results suggest that a transient Phe and NP
titration may further adversely affect metabolic control, partic-
ularly in nonresponders. Even though the use of BH4 has been
described as a good coadjuvant for BH4 responders, there are
many different protocols for assessing BH4 responsiveness. A
multicenter and controlled study would be helpful to examine
the long-term effect of different methodologies on metabolic
control, including a review of length and strategy of prepara-
tion for the LT and the assessment of its relevance.
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